CytoDyn Inc. CYDY

Company Overview

CytoDyn Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of therapies targeting immune modulation and viral diseases through CCR5 receptor antagonism. The company’s primary asset is leronlimab, a humanized monoclonal antibody designed to block the CCR5 receptor, which has been studied across multiple therapeutic areas including oncology, HIV, inflammation, and immune-related disorders. CytoDyn operates within the biotechnology and biopharmaceutical industries and does not currently market an approved commercial product, with revenue historically derived primarily from financing activities rather than recurring product sales.

The company was founded in 2002 and is headquartered in Vancouver, Washington. CytoDyn initially concentrated on HIV treatment development before expanding the clinical focus of leronlimab into oncology and inflammatory diseases. Over time, the company repositioned its strategy toward evaluating CCR5 modulation in broader immunological and oncologic applications. Public filings and company disclosures indicate that CytoDyn’s strategic positioning is centered on the potential versatility of a single biologic platform across multiple disease indications, although the company remains dependent on clinical development progress, regulatory interactions, and capital access.